|
|
Nonregulatory announcementECDC report shows HAIs are increasing antibiotic useA third of microorganisms causing HAIs healthcareassociated infections were found to be resistant to antibiotics, leaving doctors with fewer effective treatment options for patientsVANCOUVER, BC / ACCESSWIRE / May 10, 2024 / Ondine Biomedical LON:OBI: A recent report from the European Centre for... Lire le communiqué |
|
| |
|
| |
|
|
Findings include 86% of surgical site infections "SSIs" caused by bacteria from the patients own nose, skin, or gut and nearly 60% of infections are resistant to antibiotics VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / Ondine Biomedical Inc. LON:OBI, the Canadian life sciences company pioneering lightactivated antimicrobial treatments, announces new independent research published in... Lire le communiqué |
|
| |
|
| |
|
|
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations EU No. 596/2014, which is part of UK law by virtue of the European Union Withdrawal Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.Corporate and Trading UpdateSignificant revenue... Lire le communiqué |
|
| |
|
| |
|
|
Mater Hospital, North Sydney has become the first Australian hospital to use Ondine Biomedicals awardwinning lightactivated antimicrobial technology VANCOUVER, BC / ACCESSWIRE / April 22, 2024 / Ondine Biomedical Inc. LSE:OBI, the Canadian life sciences company pioneering lightactivated antimicrobial treatments, announces that Mater Hospital, North Sydney, a private hospital in New South Wales,... Lire le communiqué |
|
| |
|
| |
|
|
New data shows reduced cardiac infections and significant cost savings after the lightactivated antimicrobial, Steriwave, replaced the antibiotic standard of care at the Mazankowski Alberta Heart InstituteVANCOUVER, CANADA / ACCESSWIRE / April 15, 2024 / Ondine Biomedical Inc. LON:OBI, the Canadian life sciences company pioneering lightactivated antimicrobial treatments, announces that an... Lire le communiqué |
|
| |
|
| |
|
|
Steriwave authorized for use by HCA UKLightactivated antimicrobial that does not generate antimicrobial resistance AMR approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UKVANCOUVER, BC / ACCESSWIRE / April 10, 2024 / Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® lightactivated antimicrobial developed... Lire le communiqué |
|
| |
|
| |
|
|
Following interest from Canadian Hospitals, Ondine prepares to enter the Intensive Care Unit ICU marketTreatment of patients in ICUs would significantly expand Ondines potential market opportunity.Hundreds of thousands of patients are admitted to the ICU every year in Canada alone, with an average stay of over four days. [1]One in every eight patients in Canadi... Lire le communiqué |
|
| |
|
| |
